A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MET exon 14 skipping mutations are known biomarkers for targeted therapy in lung cancer.
• MET tyrosine kinase inhibitors (TKIs) show variable efficacy, necessitating deeper understanding of different MET alteration subtypes.
• Current detection methods may not capture all relevant MET alterations.

Discussion:

• A novel MET c.3028+2 T>A mutation, predicted to cause MET exon 14 skipping, was identified in a lung adenocarcinoma patient via next-generation sequencing (NGS).
• The identified mutation was validated using immunohistochemistry (IHC) and quantitative polymerase chain reaction (qPCR).
• The patient achieved a positive therapeutic response to crizotinib, a MET TKI, highlighting the clinical relevance of this specific mutation.

Key Insights:

• This is the first report to verify a MET exon 14 skipping variant using multiple methodologies and demonstrate its clinical efficacy with MET TKI treatment.
• The findings expand the known spectrum of MET exon 14 skipping variants.
• The study suggests that MET inhibitors may be applicable to patients with MET c.3028+2 T>A/C/G mutations.

Outlook:

• Targeted NGS analysis holds promise for enhancing the detection of MET alterations in clinical practice.
• Further research into diverse MET exon 14 skipping subtypes could refine patient selection for MET-targeted therapies.
• This work supports the broader application of MET inhibitors in lung adenocarcinoma based on specific genetic profiles.